Nobilis Therapeutics is developing proprietary inhalation-based therapeutics using controlled self-administration of inert gases to address unmet medical need in the treatment of psychiatric and neurodegenerative diseases.

By leveraging data on more than 500 patients successfully treated for conditions ranging from panic disorder to autoimmune diseases, Nobilis has coupled its patent pending gas mixtures with a proprietary inhalational device to offer reproducible, standardized, and controlled patient exposure. The Company is currently advancing its technologies into human clinical trials.

Twitter Feed

Nobilis Therapeutics @NobilisTx
RT @Immuneadvisors: Now I know y I love horseradish !! It blocks #inflammatory TNF alpha https://t.co/fiA38vnPVo #inflammation #autoimmu…
h J R
Nobilis Therapeutics @NobilisTx
Correlation between #inflammation protein CRP and level of #ptsd in survivors of #911 https://t.co/HDxr4rHHUz Xen… https://t.co/NyNIBMcuWj
h J R
Nobilis Therapeutics @NobilisTx
Correlation between spontaneous eye blinks and attention focusing in patients with #ptsd https://t.co/WFZa0nxkJrhttps://t.co/n4cR74M6DE
h J R
Nobilis Therapeutics @NobilisTx
Xenon is unique among NMDA receptor antagonists in that it does not produce neurotoxicity https://t.co/Rj2vaJXf5g #ptsd #ptsdawareness
h J R